ASX Health Stock: Immutep's Trial Approval, Alcidion's $4M Contract

2 min read | July 17, 2024 11:40 AM AEST | By Team Kalkine Media

Google News:

ASX Health Stock: Immutep's Trial Approval, Alcidion's $4M Contract — Image source: Billion Photos, Shutterstock

Recent News

Santos (ASX:STO) After the Takeover Collapse: Bargain or Value Trap?

Why Pro Medicus (ASX:PME) Is Leading the Growth Stock Conversation

Is 360 (ASX:360) Amid ASX 200 Revealing Growth’s New Reality?

Why 360 (ASX:360) ASX 200 Is Facing a New Growth Test

Make Kalkine Media
My Trusted Source

Headline

Alcidion Signs $4M Contract for Patient Care Platform with HRHA

Immutep and Alcidion Make Strides with Key Approvals and Contracts

Immutep Receives Approval for Phase 1 Trial of Autoimmune Therapy

Immutep (ASX: IMM), a biotech company specializing in LAG-3 immunotherapies, has received regulatory clearance from the Netherlands for its Phase I clinical trial of IMP761. This first-in-human trial marks a significant milestone in the development of IMP761, a LAG-3 agonist antibody aimed at treating autoimmune diseases like rheumatoid arthritis, Type 1 diabetes, and multiple sclerosis.

Previous trials have shown that blocking LAG-3 in cancer patients can enhance anti-tumor T cell responses, leading to autoimmunity in some cases. IMP761 aims to restore immune balance by enhancing LAG-3's ability to suppress self-reactive T cells that contribute to autoimmune diseases. Dr. Frédéric Triebel, Immutep's Chief Scientific Officer, emphasized the innovative approach of using IMP761 to target aggressive T cells responsible for these conditions.

The Phase I study, which is placebo-controlled and double-blind, will enroll 49 healthy volunteers to evaluate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of IMP761. The Centre for Human Drug Research (CHDR) in Leiden, Netherlands, will use a unique test involving keyhole limpet haemocyanin (KLH) to assess IMP761's effects in the human body. Immutep expects to enroll the first participants in Q3 of this year, with initial data available by the end of the year.

Alcidion Secures $4M Contract

Medtech firm Alcidion Group (ASX:ALC) has signed a long-term partnership with Hume Rural Health Alliance (HRHA) to implement its Miya Precision platform, focusing on improving patient flow and virtual care. This $4 million agreement, spanning five years, will primarily be recognized as annual subscription revenue.

Awarded after thorough market analysis by HRHA and advice from Infrastructure Advisory Group, the Miya Precision platform will enhance bed availability management across the region, streamlining patient care. The platform integrates essential information into central dashboards, allowing caregivers to make clinical decisions directly at the point of care.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.